Our Blog
The Voice of the Patient: Lessons from a Wilson Disease Roundtable
May 27, 2026
By Robert Fetty, Account Manager, PANTHERx Rare Earlier this spring, I attended the Wilson Disease Association for its 2026 Spring Support Symposium in Ann Arbor, Michigan....
How Rare Disease Therapy Launches Will Adapt | Pharmaceutical Commerce
May 8, 2026
Austin Russian discusses the advantages and challenges of manufacturers taking a more active role in the patient journey, as well as how rare disease and cell and gene therapy launches are evolving.
How Fragmentation Delays Rare Disease Therapy Access | Pharmaceutical Commerce
May 5, 2026
Live from Asembia AXS26, Austin Russian explains how access to rare disease treatments can be delayed.
From Hope to Access: Three Lessons From the Front Lines of Rare Disease Launches
April 30, 2026
Every day, our work is guided by one question: how do we help people with rare diseases get the treatments they need so they can focus on living their lives, not navigating systems?
The Rare Journey Needs a Special Pharmacy Partner
Drug Channels Institute | March 27, 2026
PANTHERx Rare’s CEO, Bansi Nagji, authored an insightful guest post for Drug Channels Institute titled, “The Rare Journey Needs a Special Pharmacy Partner.” He makes...
From Insight to Intention: What the Rare Disease Community Is Asking of Itself
March 24, 2026
I recently had the privilege to serve as a Co-Chair of this year’s Access USA Rare Disease Summit, which means I had the privilege of...
Patient-centric care needs to be at the epicenter of CGT expansion
February 18, 2026
Dr. Jastrab speaks on a panel at Advanced Therapies Week in February 2026. By Abigail Jastrab, PharmD, BCPS Director, Patient Engagement and Clinical Innovation As...
Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different
Drug Channels Institute | January 9, 2026
In this Drug Channels Institute guest post, “Targeted Reach, Tighter Relationships: Why Rare Disease Launches Are Different,” PANTHERx’s Chief Commercial & Clinical Officer, Dr. Richard...
PANTHERx Rare Submits Comment Letter for FDA’s Rare Disease Innovation, Science and Exploration (RISE) Workshop Series
January 5, 2026
Dr. Richard Faris, our Chief Commercial and Clinical Officer, recently submitted a proposal on behalf of PANTHERx in response to the FDA’s request for public...
Inside Rare Disease Pharmacy: Lessons in Personalizing Care
Drug Channels Institute | September 12, 2025
Bansi explores how the emerging model of “Rare Pharmacy” addresses the challenges rare diseases pose to patients, caregivers, and the healthcare system. His perspective highlights...